Abstract
Despite the introduction of statins for lowering LDL-C level, atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of death and morbidity worldwide. Combination therapies with statin and other lipid-lowering drugs, including ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, have unlocked additive benefits for treatment of ASCVD, but morbidity and mortality due to ASCVD remain high. New anti-inflammatory therapies have emerged for treatment and prevention of ASCVD to address these problems. Canakinumab neutralization of interleukin-1β (IL-1β) is the only verified therapy, and low-dose methotrexate holds promise due to its efficacy and safety for treatment of ASCVD. However, many agonistic and antagonistic candidates within inflammation pathways have failed to develop into useful drugs for ASCVD because of the complexity of the inflammatory process in atherosclerosis. In this review, we outline current and future pharmaceutical therapies for ASCVD in terms of lipid-modifying strategies and anti-inflammation treatments.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of death and morbidity worldwide, despite the introduction of statins about 30 years ago (Benjamin et al. 2018). The pathogenesis of atherosclerosis is initiated by endothelial dysfunction and structural alterations of arterial walls triggered by disturbed laminar stress and elevated circulating apolipoprotein B (apoB)-containing lipoprotein, mainly low-density lipoprotein (LDL) (Kwon et al. 2008; Moore and Tabas 2011). Exposure of sub-endothelial proteoglycans caused by structural alterations of the aorta leads to accumulation of LDL under the endothelial layer through binding with apoB (Kwon et al. 2008). LDL particles in the intima are readily modified by reactive oxygen species, which trigger expression of adhesion molecules and release of chemokines on endothelial cells, leading to recruitment of immune cells in the intima (Weber and Noels 2011). Macrophages retained in the intima engulf modified LDLs such as oxidized LDL (oxLDL) through scavenger receptors, which drive the transformation of macrophages into foam cells (Sakakura et al. 2013). In addition to foam cell formation, macrophages express various costimulatory molecules that activate other immune cells to create inflammatory conditions in lesions (Weber and Noels 2011). In the process of atheroma propagation, accumulation of apoptotic cells, debris, and cholesterol crystals contributes to development of the necrotic core and in turn to plaque destabilization, leading to plaque rupture or erosion (Ylä-Herttuala et al. 2011). Occlusive thrombosis formed by plaque rupture or erosion causes acute cardiovascular events, which underlie mortality due to ASCVD (Sakakura et al. 2013). Rupture-prone plaques consist of large necrotic cores with thin fibrous caps, plaque hemorrhages, neovascularization, and adventitial inflammation (Ylä-Herttuala et al. 2011).
Given the pathophysiology of atherosclerosis (Fig. 1), current therapeutic targets and drugs for ASCVD emphasize normalization of plasma lipids including LDL-cholesterol (LDL-C) and high-density lipoprotein-cholesterol (HDL-C) and attenuation of inflammation in lesions (Weber and Noels 2011; Shapiro and Fazio 2016). In this review, we describe and discuss current and future pharmaceutical therapies for ASCVD in terms of lipid-modifying strategies and anti-inflammation treatments.
Lipid-modifying therapies
Risk factors for ASCVD include dyslipidemia, hypertension, diabetes, cigarette smoking, and genetic mutations (Bergheanu et al. 2017; Jellinger et al. 2017) (Fig. 2). Among these, hypercholesterolemia is considered a major risk factor for ASCVD (Nelson 2013). Clinical and experimental data have shown that plasma cholesterol, especially LDL-C, is the catalyst for development of ASCVD (Pedersen et al. 1994; Finking and Hanke 1997). Statin mega-trials based on 26 randomized trials of statins indicate that major ASCVD events and mortality are reduced by 22% and 10%, respectively, after reduction of 39 mg/dL in LDL-C level (Cholesterol Treatment Trialists’ et al. 2010). In addition, HDL-C level, hypertriglyceridemia, and lipoprotein(a) (Lp(a)) are considered independent risk factors for ASCVD (Rubin et al. 1991; Elam et al. 2000; Kronenberg and Utermann 2013; Catapano et al. 2017; Jellinger et al. 2017). Although low levels of HDL-C are well correlated with ASCVD, high levels of HDL-C are not related to atheroprotection, indicating that functional HDL level is important (Catapano et al. 2017). Hypertriglyceridemia is a traditional risk factor for ASCVD, but the benefits associated with lower levels of TG in patients with ASCVD are modest (Catapano et al. 2017). Elevated Lp(a), which consists of an LDL-like particle with apolipoprotein A (apoA), has emerged as a risk factor in patients with ASCVD or with strong family history of ASCVD (Kamstrup et al. 2009). In this section, we describe current and future drug therapies and therapeutic targets for regulation of lipid levels in patients with ASCVD (Table 1).
Statins
After discovery of the first cholesterol-lowering drug, mevastatin (ML-236B), which is produced by the fungus Penicillium citrinum, lovastatin (mevinolin, MK803) was derived from the fungus Aspergillus terreus and marketed as a cholesterol-lowering drug (Brown et al. 1976). In 1994, the Scandinavian Simvastatin Survival Study (4S) evaluated the cholesterol-lowering effects of simvastatin (20–40 mg/day) on mortality and morbidity in 4444 patients with coronary heart disease (CHD), concluding that simvastatin reduced LDL-C by 35%, total mortality by 30%, and major coronary events by 34% compared to placebo (Pedersen et al. 1994). Follow-up trials have consistently shown that statins effectively reduce morbidity and mortality in high-risk patients with ASCVD and in generally healthy people. The Cholesterol and Recurrent Events (CARE) study determined that administration of pravastatin (40 mg/day) resulted in an absolute decrease of 3% (10.2% in the pravastatin group; 13.2% in the placebo group) in the study end point of frequency of fatal coronary events or nonfatal myocardial infarctions (Sacks et al. 1996). The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study concluded that pravastatin (40 mg/day) treatment resulted in a relative risk reduction of 24% for mortality from CHD as the primary outcome (Long-Term Intervention with Pravastatin in Ischaemic Disease Study 1998). The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) showed that lovastatin (20–40 mg/day) reduced the risk of first acute major coronary events (116 in the lovastatin group; 183 in the placebo group) in generally healthy men and women with average total cholesterol (TC) and LDL-C and below-average HDL-C levels (Downs et al. 1998). Overall, previous trials determined that statins safely reduce morbidity and mortality due to ASCVD, and that 1% reductions of LDL-C produced 1% reductions of ASCVD events, indicating the importance of managing LDL-C level in patients with ASCVD (Cholesterol Treatment Cholesterol Treatment Trialists’ (CTT) Collaboration et al. 2010). Statins show potential to lower LDL-C, but residual risks remained high in statin-treated ASCVD patients. Therefore, the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) study investigated the optimal level of LDL-C by comparing results of administration of pravastatin (40 mg/day, standard therapy) and atorvastatin (80 mg/day, intensive therapy) (Cannon et al. 2004). The primary end point, which was rate of combined death from ASCVD, was 26.3% in the pravastatin group and 22.4% in the atorvastatin group, indicating a 16% reduction of relative risk after intensive atorvastatin therapy. Mills et al. suggested that intensive statin therapy reduces the risk of non-fatal events but not of CVD deaths in a meta-analysis of randomized clinical trials (Mills et al. 2011). However, they found that intensive statin therapy reduced mortality in patients with acute coronary syndrome.
Collectively, well conducted clinical trials demonstrate that statin therapy produces remarkable results (Table 2), including consistent benefits associated with reduction in rate of ASCVD without major adverse effects. Nevertheless, two-thirds of statin-treated patients with ASCVD experience reoccurrence of CVD events, and some patients are unsuitable for statin therapy because of therapeutic intolerance to statins or side effects. Therefore, developing new therapeutic targets and drugs remains critical.
Ezetimibe
Ezetimibe is recommended as second line therapy for patients with statin intolerance or who are unable to reach goal LDL-C level with statin therapy alone (Jellinger et al. 2017). Ezetimibe inhibits dietary cholesterol absorption in the intestine by targeting the Niemann-Pick C1-like 1 (NPC1L1) protein at the jejunal enterocyte brush border (Phan et al. 2012; Cannon et al. 2015). In a meta-analysis of randomized controlled trials, ezetimibe monotherapy significantly changed levels of TC (− 13.46%), LDL-C (− 18.58%), HDL-C (+ 3.00%), and TG (− 8.06%) compared to placebo control (Pandor et al. 2009). In combination therapy with statin, ezetimibe induced incremental reduction of LDL-C by 23–24% (Cannon et al. 2015). Although early ezetimibe/statin combination trials showed non-significant differences in aortic stenosis compared to statin alone (Kastelein et al. 2005; Rossebø et al. 2008), recent trials revealed beneficial effects of ezetimibe/statin combination therapy in patients with ASCVD (Baigent et al. 2011; Cannon et al. 2015; Tsujita et al. 2015). A combination therapy of ezetimibe (10 mg/day) and simvastatin (40 mg/day) improved Kaplan–Meier event rates of the primary study end point by 2% compared to simvastatin monotherapy in the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) (Cannon et al. 2015), and ezetimibe/atorvastatin combination resulted in greater coronary plaque regression than atorvastatin monotherapy in the Plaque Regression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by Intravascular Ultrasound (PRECISE-IVUS) study (Tsujita et al. 2015). These studies support the use of ezetimibe as second line therapy for statin-intolerant patients with ASCVD.
PCSK9 inhibitor
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease highly expressed in the liver and binds to LDL-R to catalyze its degradation in lysosomes, leading to elevated LDL-C level in serum (Seidah et al. 2014). Abifadel et al. reported that a gain-of-function by missense mutation of the PCSK9 gene in a French family caused autosomal dominant hypercholesterolemia (ADH), which is characterized by increase in LDL-C level (Abifadel et al. 2003). In contrast, loss-of-function mutations due to two nonsense mutations (Y142X and C679X) in the PCSK9 gene decrease serum LDL-C level in African-Americans, and Cohen et al. found that nonsense mutations in PCSK9 reduced the incidence of coronary events (Cohen et al. 2005, 2006). Therefore, clinical development programs are focusing on developing therapeutic antagonists of PCSK9 (Table 3).
Two fully human monoclonal antibodies (AMG145 = evolocumab and REGN727 = alirocumab) were validated as inhibitors of PCSK9 in terms of efficacy and safety in patient trials (Robinson et al. 2015; Sabatine et al. 2015). Evolocumab plus standard therapy reduced LDL-C level by 61% and rate of CVD events from 2.18% after standard therapy to 0.95% in patients at high risk for CVD events (Sabatine et al. 2015). Combination therapy of alirocumab and statins at the maximum tolerated dose produced a 62% change from baseline in LDL-C level and reduced the rate of CVD events compared to single therapy in patients at high risk for CVD events (Robinson et al. 2015). The two antibodies have been verified for safety and efficacy for patients at high risk for CVD in several clinical trials (Navarese et al. 2015; Nicholls et al. 2016). Further, combination therapy with PCSK9 inhibitor was examined in the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial of evolocumab and in the Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab (ODYSSEY Outcomes) trial of alirocumab, in which statins were associated with significantly reduced serum LDL-C level and a composite endpoint of cardiovascular death without major adverse effects in stable or unstable ASCVD patients, respectively (Sabatine et al. 2017; Schwartz et al. 2018).
In the ORION-1 clinical trial, inclisiran, a synthesized small interfering RNA targeting PCSK9 messenger RNA (mRNA), produced promising results in that both single-dose regimens (200, 300, or 500 mg of inclisiran) and two-dose regimens (100, 200, or 300 mg of inclisiran) maintained reductions of PCSK9 (single-dose regimen, from 47.9 to 59.3% and two-dose regimen, 53.2 to 69.1%) and LDL-C level (single-dose regimen, from 27.9 to 41.9% and two-dose regimen, 35.5 to 52.6%) at day 180 (Ray et al. 2017). In comparison with monoclonal antibodies, inclisiran has the potential advantage of decreasing the number of injections and amount of drug required for therapeutic effect.
Omega-3 polyunsaturated fatty acids
Omega-3 polyunsaturated fatty acids (PUFAs) have beneficial effects including lowering TG, enhancing endothelial function, vasodilation, decreasing platelet aggregation ability, and decreasing myocyte excitability (Mozaffarian and Wu 2012). Early clinical trials have shown beneficial effects of omega-3 PUFAs on mortality due to ASCVD (GISSI-Prevenzione Investigators 1999; Yokoyama et al. 2007; Tavazzi et al. 2008), but recent trials and meta-analyses failed to replicate the beneficial effects seen in early trials (Kromhout et al. 2010; Kwak et al. 2012). In a recent systematic review and meta-analysis of 20 studies of 63,630 subjects, Kotwal et al. concluded that omega-3 PUFAs had no overall effects on composite cardiovascular events such as myocardial infarction, stroke, or cardiovascular death [relative risk (RR) 0.96; 95% confidence interval (CI) 0.90–1.03; P = 0.24) or on total mortality (RR 0.95; 95% CI 0.86–1.04; P = 0.28) (Kotwal et al. 2012). However, omega-3 PUFAs exhibited protective effects against vascular death (RR 0.86; 95% CI 0.75–0.99; P = 0.03). In addition, the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDECE-IT) reported that a primary endpoint event occurred in 17.2% of patients treated with icosapent ethyl (total daily dose, 4 g) and purified and stable eicosapentaenoic acid (EPA) compared with 22.0% of the placebo group (Bhatt et al. 2019). The STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia study (STRENGTH), another large prospective randomized controlled outcomes trial planned for 2019, will determine whether Epanova (4 g/day) has beneficial effects against cardiovascular events in statin-treated high risk patients (Nicholls et al. 2018).
Other lipid-lowering agents
- Bempedoic acid (ETC-1002)
Adenosine triphosphate citrate lyase (ACL) is a cytosolic enzyme that is highly expressed in liver and white adipose tissue and is involved in fatty acid and cholesterol biosynthesis through catalyzing acetyl CoA synthesis (Bilen and Ballantyne 2016). ETC-1002, which is a first-in-class, oral, once-daily, small molecule cholesterol synthesis inhibitor, has two major modes of action in inhibition of ACL and activation of AMP-activated protein kinase (AMPK) (Pinkosky et al. 2013). ETC-1002 lowered LDL-C level in patients with hypercholesterolemia by 30% when used as monotherapy, by 48% as part of a combination therapy with ezetimibe (10 mg), and by an additional 22% when used in combination with atorvastatin (10 mg) (Bilen and Ballantyne 2016; Thompson et al. 2016). In addition, ETC-1002 treatment increased the activity of AMPK, a metabolic sensor involved in gluconeogenesis, β-oxidation of fatty acids, mitochondrial density, and inflammatory signaling, resulting in clinical favorable effects on CVD risk factors including hyperglycemia and insulin resistance (Pinkosky et al. 2013; Bilen and Ballantyne 2016). Indeed, ETC-1002 treatment lowered LDL-C level (39%), fasting plasma glucose (− 8.5%), and hsCRP (41%) in patients with hypercholesterolemia and type 2 diabetes mellitus compared to placebo (Gutierrez et al. 2014). Pinkosky et al. demonstrated that ETC-1002 inhibits cholesterol biosynthesis in the liver but not in skeletal muscle because of the tissue distribution of very long-chain acyl-CoA synthetase-1 (ACSVL1), which modulates ETC-1002 (inactive form) to ETC-1002-CoA (active form) (Pinkosky et al. 2016). Thus, ETC-1002 is a potent drug for dramatically reducing the incidence of diabetes mellitus and myotoxicity associated with statin therapy.
Mipomersen
Mipomersen, a synthetic single-strand apoB antisense oligonucleotide (ASO), binds to mRNA coding for apoB-100 and accelerates the degradation of mRNA by the enzyme ribonuclease H (Bell et al. 2011). Mipomersen was developed to treat homozygous familial hypercholesterolemia (HoFH). In clinical trials, mipomersen reduced apoB level (25–34%), LDL-C level (28–36%), and Lp(a) (21–33%) in patients with HoFH, but 18% of patients receiving mipomersen stopped taking the drug due to adverse effects such as skin reactions at the injection site, liver damage, and flu-like symptoms (Raal et al. 2010; McGowan et al. 2012; Stein et al. 2012; Thomas et al. 2013).
Lomitapide
Lomitapide is a small molecule inhibitor of microsomal triglyceride transfer protein (MTP or MTTP), which transfers lipids to apoB in the endoplasmic reticulum to assemble very low-density lipoprotein (VLDL) and chylomicrons (Gregg and Wetterau 1994; Rader and Kastelein 2014). Lomitapide (40 mg/day) reduced level of LDL-C by 50% at 26 weeks and by 38% at week 78 in patients with HoFH, with adverse effects including gastrointestinal symptoms due to increased TG of enterocytes, hepatic fat accumulation, and elevation of transaminases (Cuchel et al. 2013).
Emerging targets
Angiopoietin-like 3 (ANGPTL3)
Loss-of-function mutations in the ANGPTL3 gene are associated with reductions of plasma TG, LDL-C, and HDL-C levels, inspiring the development of therapeutic agents targeting ANGPTL3 in ASCVD (Robciuc et al. 2013). ANGPTL3 acts as a dual inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL), resulting in elevation of plasma TG, LDL-C, and HDL-C levels (Fujimoto et al. 2006; Lee et al. 2009). In a clinical trial, ANGPTL3-LRx, an antisense inhibitor of ANGPTL3, resulted in reductions of TG (33.2% to 63.1%), LDL-C (1.3% to 32.9%), and total cholesterol (8.7% to 34.3%) in healthy adults (Graham et al. 2017). Dewey et al. verified that evinacumab, a human monoclonal antibody against ANGPTL3, decreased atheroma and necrotic core size compared to a control antibody in dyslipidemic mice, and that evinacumab reduced fasting TG level by 76% and LDL-C level by 23% in healthy human volunteers, highlighting its possible use as a new therapeutic agent against ASCVD (Dewey et al. 2017).
Lipoprotein(a)
Genetic studies and epidemiologic studies consistently suggest that Lp(a) is an independent risk factor for ASCVD (Danesh et al. 2000; Kamstrup et al. 2009). Lp(a) consists of one molecule of apo(a) linked to one molecule of apoB-100 of the LDL-like particle (Albers et al. 1996). Due to its structural similarity to plasminogen and tissue plasminogen activator (tPA), Lp(a) interferes with the fibrinolytic system and stimulates secretion of plasminogen activator inhibitor 1 (PAI-1), leading to atherothrombosis (Eaton et al. 1987). Lp(a) carries cholesterol and oxidized phospholipids, both of which contribute to progression of atherosclerosis through recruitment of inflammatory cells and proliferation of smooth muscle cells (Tsimikas et al. 2005; Banach 2016).
Although selective therapeutic agents that decrease Lp(a) without affecting other lipoproteins are not available, lipid-lowering drugs including niacin, mipomersen, lomitapide, PCSK9 inhibitors, cholesterol-ester-transfer protein (CETP) inhibitor, and atorvastatin reduce Lp(a) level and also affect other lipids and lipoproteins. In a phase 1/2a trial, IONIS-APO(a)-LRx, a ligand-conjugated antisense oligonucleotide targeting apo(a) designed to be highly and selectively taken up by hepatocytes, resulted in mean reduction in Lp(a) by 66% in the 10 mg group, by 80% in the 20 mg group, and by 92% in the 40 mg group, without adverse effects (Viney et al. 2016). Therefore, IONIS-APO(a)-LRx may be a potent therapy to reduce Lp(a) concentration in patients with high Lp(a)-mediated ASCVD.
Anti-inflammation therapies
Despite the importance of cholesterol in ASCVD, more than 50% of ASCVD patients treated with lipid-lowering drugs still suffer from major ASCVD events and mortality even after achieving goal LDL-C level (Castelli 1996; Libby et al. 2000; Catapano et al. 2017; Jellinger et al. 2017). This convergence of clinical findings indicates the need to develop non-lipid-lowering drugs for treatment of ASCVD (Ridker and Luscher 2014; Ridker 2016). The underlying pathogenesis of atherosclerosis involves imbalanced lipid regulation and inflammatory response, and unleashed inflammation is closely related to initiation, progression, and thrombotic complications of atherosclerosis (Weber and Noels 2011). Indeed, modified LDL such as oxLDL and glycation of LDL evokes endothelial dysfunction and recruitment of immune cells into arterial walls, propagating atheroma (Libby et al. 2011; Park and Oh 2011). Maladaptive immune responses in advanced atherosclerosis deleteriously affect the resolution of inflammation, which leads to expansion of the necrotic core and plaque destabilization (Sakakura et al. 2013). Therefore, inflammation participates in all stages of atherosclerosis from initiation to progression to destabilization, suggesting that resolving inflammation by targeting pivotal pro- or anti-inflammatory molecules or cells may be useful for giving assistance to lipid-lowering therapies (Fig. 3). In this section, we review therapeutic agents and targets thought to resolve inflammation in ASCVD.
CANTOS trial: interleukin (IL)-1β neutralizing monoclonal antibody (canakinumab)
The interleukin-1 (IL-1) family, consisting of IL-1α and IL-1β isoforms, plays important roles in the pathogenesis of atherosclerosis such as increasing adhesion molecule expression on endothelial cells, triggering vascular smooth muscle cell proliferation, and up-regulating IL-6, which induces the elevation of several acute phase reactants including hsCRP, fibrinogen, and PAI-1 on hepatocytes (Bevilacqua et al. 1985; Libby et al. 1988; Ridker et al. 2012; Ridker and Luscher 2014; Ridker 2016; Libby 2017). Dysregulation of IL-1β activation by genetic mutations causes severe inflammation and fever (Mariathasan and Monack 2007), indicating that IL-1β is a key molecule in the inflammation pathway. Therefore, modulation of IL-1β may be effective in patients with ASCVD.
Canakinumab is a fully human monoclonal antibody neutralizing IL-1β that was approved for treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), which is a spectrum of auto-inflammatory syndromes including Muckle-Wells syndrome, familial cold auto-inflammatory syndrome, and neonatal-onset multisystem inflammatory disease (Dinarello et al. 2012). In the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial, canakinumab (50, 150, 300 mg, administered subcutaneously every 3 months) was evaluated in patients with prior MI and high level of hsCRP (≥ 2 mg/L) (Ridker et al. 2017a, b; Aday and Ridker 2018). The primary end point was a composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. After 48 months, canakinumab treatment reduced hsCRP levels by 26% in the 50 mg group, by 37% in the 150 mg group, and by 41% in the 300 mg group compared to placebo, without affecting lipid levels. The incidence rate of the primary end point was 4.50 events per 100 person-years in the placebo group and 4.11, 3.86, and 3.90 events per 100 person-years in the 50, 150, and 300 mg groups, respectively. Therefore, anti-inflammatory therapy targeting IL-1β with canakinumab significantly reduced the rate of recurrent CVD events compared to placebo without affecting lipid levels.
Cardiovascular inflammation reduction trial (CIRT)
Low-dose methotrexate (10–30 mg/week) is broadly used to treat patients with cancer or autoimmune disease (Saag et al. 2008; Singh et al. 2012). When low-dose methotrexate treatment is used as an immune system suppressant in patients with rheumatologic disease, it reduces markers of inflammation, including CRP, IL-6, and tumor necrosis factor α (TNF α), without affecting lipid levels, blood pressure, or platelet function (Rho et al. 2009). In a meta-analysis, patients with rheumatologic disease receiving methotrexate treatment showed 21% lower risk of cardiovascular events compared to those receiving other anti-rheumatic therapies (Micha et al. 2011).
The CIRT is a randomized clinical trial to determine whether direct inhibition of inflammation by low-dose methotrexate (15-20 mg/week) had clinical relevance for anti-atherothrombosis in prior MI patients with type 2 diabetes or metabolic syndrome (Everett et al. 2013). The primary end point of the CIRT is a composite of nonfatal MI, nonfatal stroke, and cardiovascular death. The CIRT was stopped after 4786 patients of the planned 7000 patients had been enrolled, and the results are anticipated in 2018.
Interleukin-6 receptor (IL-6R) antagonist
IL-6 is a cytokine derived from immune cells, adipocytes, and smooth muscle cells (Tanaka et al. 2014). Although IL-6 acts as an anti-inflammatory myokine in muscle (Petersen and Pedersen 2005; Brandt and Pedersen 2010), it also stimulates inflammatory and auto-immune processes in several diseases including rheumatoid arthritis, diabetes, and atherosclerosis (Davies and Choy 2014; Tanaka et al. 2014). IL-6 is a major pro-inflammatory cytokine in the pathogenesis of atherosclerosis, stimulating production of CRP and fibrinogen from hepatocytes (Heinrich et al. 1990). Increased plasma IL-6 level is associated with mortality due to ASCVD independent of other risk factors, and genetic polymorphisms in the IL-6 signaling pathway at rs2228145 and rs7529229 are associated with lower levels of hsCRP and of vascular risk (IL6R Genetics Consortium Emerging Risk Factors Collaboration et al. 2012; Interleukin-6 Receptor Mendelian Randomisation Analysis et al. 2012).
Tocilizumab is a humanized monoclonal antibody against IL-6R that is used as an immunosuppressive drug for treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis (Fleischmann et al. 2013; Yokota et al. 2016). Despite promising observations, patients with rheumatoid arthritis who received tocilizumab exhibited significant increases of TC, LDL-C, and TG levels compared to a placebo group by week 12 (12.6% vs. 1.7%, 28.1% vs. 2.2%, 10.6% vs-1.9%, respectively), indicating major limitations in the development of IL-6 receptor antagonist treatments for ASCVD (Kawashiri et al. 2011; Strang et al. 2013).
Varespladib and darapladib
The phosholipase A2 superfamily, including secretory phospholipase A2 (sPLA2) and lipoprotein-associated phospholipase A2 (Lp-PLA2), hydrolyzes phospholipid molecules and produces potential atherogenic lipid fractions (Rosenson and Stafforini 2012). Thus, sPLA2 and Lp-PLA2 were considered potential risk factors for ASCVD in animal and observational human studies (Lp et al. 2010; Rosenson 2010; Rosenson and Hurt-Camejo 2012). However, clinical trials to evaluate the efficacy of varespladib (a non-specific sPLA2 inhibitor) and darapladib (a targeted Lp-PLA2 inhibitor) concluded that neither inhibitor had beneficial effects regarding risk of major coronary events (Mohler et al. 2008; Serruys et al. 2008; Rosenson et al. 2010). In addition, Holmes et al. reported that a genetic variant, the PLA2G2A rs 11573156 allele, was associated with reduction of sPLA2 level but not with major vascular events according to Mendelian randomization meta-analysis (Holmes et al. 2013), suggesting that sPLA2 is not a promising therapeutic target for preventing ASCVD.
Limitations and future directions
Currently, the efficacy and safety of canakinumab neutralizing IL-1β has been verified only for treatment of ASCVD. Low-dose methotrexate treatment for ASCVD is also promising in terms of efficacy and safety as a therapy for ASCVD. However, many agonistic or antagonistic candidates in inflammation pathways have failed to develop into useful drugs for treating ASCVD due to the complexity of the specific inflammatory process. To surmount this hurdle, genome-wide association studies (GWAS) would be helpful to develop new therapeutic targets and drugs for ASCVD. Genetic variants in inflammation genes and coronary artery disease including C-X-C motif ligand 12 (CXCL12), SH2B adaptor protein 3 (SH2B3), AB0, Human Leukocyte Antigen (HLA), IL-5, Platelet endothelial cell adhesion molecule 1 (PECAM1), Protein C Receptor (PROCR), and antisense non-coding RNA in the INK4 locus (ANRIL) are potential targets for development of ASCVD therapeutic agents (Fava and Montagnana 2018). Based on the pathogenesis of atherosclerosis, studying targets regulating systemic and/or local lipid metabolism might be helpful to gain insights useful for development of drugs against ASCVD. A small number of adipokines, including adiponectin and retnla, exhibit anti-obesity and anti-inflammatory properties, leading to reduction of atherosclerosis in experimental studies (Okamoto et al. 2002, 2008; Lee et al. 2014). Recently, we proposed that oxidative stress activates macroautophagy/autophagy and contributes to atherogenesis via lipophagic flux, which maintains lowered intracellular cholesterol mass in macrophages (Jeong et al. 2018). This leads to the possibility of using oxidative stress as a novel therapeutic target to regulate macrophage cholesterol homeostasis against ASCVD.
Conclusion
The morbidity and mortality caused by ASCVD have been reduced by lowering LDL-C level through statin therapy, which is a great cornerstone for treatment and prevention of ASCVD. Combination therapies with statins and other lipid-lowering drugs including ezetimibe and PCSK9 inhibitors have yielded additive benefits for treatment of ASCVD. In addition, anti-inflammatory therapies, including canakinumab and low-dose methotrexate, hold promise due to their efficacy and safety for treatment of ASCVD. Although the rate of ASCVD events is significantly reduced by administration of current lipid-lowering drugs and anti-inflammatory agents, morbidity and mortality remain high in ASCVD patients. Constant efforts for development of new therapeutic targets based on GWAS and molecular lipid metabolism would pave the way to a new era of precision medicine for treatment of patients with ASCVD.
References
Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derré A, Villéger L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34(2):154–156. https://doi.org/10.1038/ng1161
Aday AW, Ridker PM (2018) Antiinflammatory therapy in clinical care: the CANTOS trial and beyond. Front Cardiovasc Med 5:62. https://doi.org/10.3389/fcvm.2018.00062
Albers JJ, Kennedy H, Marcovina SM (1996) Evidence that Lp[a] contains one molecule of apo[a] and one molecule of apoB: evaluation of amino acid analysis data. J Lipid Res 37(1):192–196
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R, Investigators SHARP (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377(9784):2181–2192. https://doi.org/10.1016/S0140-6736(11)60739-3
Banach M (2016) Lipoprotein (a)-we know so much yet still have much to learn. J Am Heart Assoc. https://doi.org/10.1161/JAHA.116.003597
Bell DA, Hooper AJ, Burnett JR (2011) Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opin Investig Drugs 20(2):265–272. https://doi.org/10.1517/13543784.2011.547471
Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O’Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee (2018) Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation 137(12):e67–e492. https://doi.org/10.1161/CIR.0000000000000558
Bergheanu SC, Bodde MC, Jukema JW (2017) Pathophysiology and treatment of atherosclerosis: current view and future perspective on lipoprotein modification treatment. Neth Heart J 25(4):231–242. https://doi.org/10.1007/s12471-017-0959-2
Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA Jr (1985) Interleukin-1 activation of vascular endothelium. Effects on procoagulant activity and leukocyte adhesion. Am J Pathol 121(3):394–403
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM, REDUCE-IT Investigators (2019) Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. https://doi.org/10.1056/NEJMoa1812792
Bilen O, Ballantyne CM (2016) Bempedoic Acid (ETC-1002): an investigational inhibitor of ATP citrate lyase. Curr Atheroscler Rep 18(10):61. https://doi.org/10.1007/s11883-016-0611-4
Brandt C, Pedersen BK (2010) The role of exercise-induced myokines in muscle homeostasis and the defense against chronic diseases. J Biomed Biotechnol 2010:520258. https://doi.org/10.1155/2010/520258
Brown AG, Smale TC, King TJ, Hasenkamp R, Thompson RH (1976) Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J Chem Soc Perkin Trans 1(11):1165–1170
Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350(15):1495–1504. https://doi.org/10.1056/NEJMoa040583
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, Investigators IMPROVE-IT (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372(25):2387–2397. https://doi.org/10.1056/NEJMoa1410489
Castelli WP (1996) Lipids, risk factors and ischaemic heart disease. Atherosclerosis 124(Suppl):S1–S9
Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Monique Verschuren WM, Vlachopoulos C, Wood DA, Luis Zamorano J, Contributor Additional, Cooney MT (2017) 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 37(39):2999–3058. https://doi.org/10.1093/eurheartj/ehw272
Chhatriwalla AK, Nicholls SJ, Nissen SE (2006) The ASTEROID trial: coronary plaque regression with high-dose statin therapy. Future Cardiol 2(6):651–654. https://doi.org/10.2217/14796678.2.6.651
Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376(9753):1670–1681. https://doi.org/10.1016/S0140-6736(10)61350-5
Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37(2):161–165. https://doi.org/10.1038/ng1509
Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354(12):1264–1272. https://doi.org/10.1056/NEJMoa054013
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, CARDS investigators (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435):685–696. https://doi.org/10.1016/S0140-6736(04)16895-5
Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK, Gaudet D, Stefanutti C, Vigna GB, Du Plessis AM, Propert KJ, Sasiela WJ, Bloedon LT, Rader DJ, Phase 3 HoFH Lomitapide Study investigators (2013) Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 381(9860):40–46. https://doi.org/10.1016/S0140-6736(12)61731-0
Danesh J, Collins R, Peto R (2000) Lipoprotein(a) and coronary heart disease.Meta-analysis of prospective studies. Circulation 102(10):1082–1085
Davies R, Choy E (2014) Clinical experience of IL-6 blockade in rheumatic diseases - implications on IL-6 biology and disease pathogenesis. Semin Immunol 26(1):97–104. https://doi.org/10.1016/j.smim.2013.12.002
Dewey FE, Gusarova V, Dunbar RL, O’Dushlaine C, Schurmann C, Gottesman O, McCarthy S, Van Hout CV, Bruse S, Dansky HM, Leader JB, Murray MF, Ritchie MD, Kirchner HL, Habegger L, Lopez A, Penn J, Zhao A, Shao W, Stahl N, Murphy AJ, Hamon S, Bouzelmat A, Zhang R, Shumel B, Pordy R, Gipe D, Herman GA, Sheu WHH, Lee IT, Liang KW, Guo X, Rotter JI, Chen YI, Kraus WE, Shah SH, Damrauer S, Small A, Rader DJ, Wulff AB, Nordestgaard BG, Tybjærg-Hansen A, van den Hoek AM, Princen HMG, Ledbetter DH, Carey DJ, Overton JD, Reid JG, Sasiela WJ, Banerjee P, Shuldiner AR, Borecki IB, Teslovich TM, Yancopoulos GD, Mellis SJ, Gromada J, Baras A (2017) Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med 377(3):211–221. https://doi.org/10.1056/NEJMoa1612790
Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11(8):633–652. https://doi.org/10.1038/nrd3800
Downs JR, Clearfield M, Weis S, Whitney E, Shapiro, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279(20):1615–1622
Eaton DL, Fless GM, Kohr WJ, McLean JW, Xu QT, Miller CG, Lawn RM, Scanu AM (1987) Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA 84(10):3224–3228
Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, Kostis JB, Sheps DS, Brinton EA (2000) Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial disease multiple intervention trial. JAMA 284(10):1263–1270
Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, Gupta M, Clearfield M, Libby P, Hasan AA, Glynn RJ, Ridker PM (2013) Rationale and design of the cardiovascular inflammation reduction trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 166(2):199–207. https://doi.org/10.1016/j.ahj.2013.03.018
Fava C, Montagnana M (2018) Atherosclerosis is an inflammatory disease which lacks a common anti-inflammatory therapy: how human genetics can help to this issue. A narrative review. Front Pharmacol 9:55. https://doi.org/10.3389/fphar.2018.00055
Finking G, Hanke H (1997) Nikolaj Nikolajewitsch Anitschkow (1885-1964) established the cholesterol-fed rabbit as a model for atherosclerosis research. Atherosclerosis 135(1):1–7
Fleischmann RM, Halland AM, Brzosko M, Burgos-Vargas R, Mela C, Vernon E, Kremer JM (2013) Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. J Rheumatol 40(2):113–126. https://doi.org/10.3899/jrheum.120447
Fujimoto K, Koishi R, Shimizugawa T, Ando Y (2006) Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity. Exp Anim 55(1):27–34
GISSI-Prevenzione Investigators (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 354(9177):447–455
Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, Baker BF, Pham NC, Digenio A, Hughes SG, Geary RS, Witztum JL, Crooke RM, Tsimikas S (2017) Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. N Engl J Med 377(3):222–232. https://doi.org/10.1056/NEJMoa1701329
Gregg RE, Wetterau JR (1994) The molecular basis of abetalipoproteinemia. Curr Opin Lipidol 5(2):81–86
Gutierrez MJ, Rosenberg NL, Macdougall DE, Hanselman JC, Margulies JR, Strange P, Milad MA, McBride SJ, Newton RS (2014) Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 34(3):676–683. https://doi.org/10.1161/ATVBAHA.113.302677
Heinrich PC, Castell JV, Andus T (1990) Interleukin-6 and the acute phase response. Biochem J 265(3):621–636
Holmes MV, Simon T, Exeter HJ, Folkersen L, Asselbergs FW, Guardiola M, Cooper JA, Palmen J, Hubacek JA, Carruthers KF, Horne BD, Brunisholz KD, Mega JL, van Iperen EPA, Li M, Leusink M, Trompet S, Verschuren JJW, Hovingh GK, Dehghan A, Nelson CP, Kotti S, Danchin N, Scholz M, Haase CL, Rothenbacher D, Swerdlow DI, Kuchenbaecker KB, Staines-Urias E, Goel A, van ‘t Hooft F, Gertow K, de Faire U, Panayiotou AG, Tremoli E, Baldassarre D, Veglia F, Holdt LM, Beutner F, Gansevoort RT, Navis GJ, Mateo Leach I, Breitling LP, Brenner H, Thiery J, Dallmeier D, Franco-Cereceda A, Boer JMA, Stephens JW, Hofker MH, Tedgui A, Hofman A, Uitterlinden AG, Adamkova V, Pitha J, Onland-Moret NC, Cramer MJ, Nathoe HM, Spiering W, Klungel OH, Kumari M, Whincup PH, Morrow DA, Braund PS, Hall AS, Olsson AG, Doevendans PA, Trip MD, Tobin MD, Hamsten A, Watkins H, Koenig W, Nicolaides AN, Teupser D, Day INM, Carlquist JF, Gaunt TR, Ford I, Sattar N, Tsimikas S, Schwartz GG, Lawlor DA, Morris RW, Sandhu MS, Poledne R, Maitland-van der Zee AH, Khaw KT, Keating BJ, van der Harst P, Price JF, Mehta SR, Yusuf S, Witteman JCM, Franco OH, Jukema JW, de Knijff P, Tybjaerg-Hansen A, Rader DJ, Farrall M, Samani NJ, Kivimaki M, Fox KAA, Humphries SE, Anderson JL, Boekholdt SM, Palmer TM, Eriksson P, Paré G, Hingorani AD, Sabatine MS, Mallat Z, Casas JP, Talmud PJ (2013) Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol 62(21):1966–1976. https://doi.org/10.1016/j.jacc.2013.06.044
IL6R Genetics Consortium Emerging Risk Factors Collaboration, Sarwar N, Butterworth AS, Freitag DF, Gregson J, Willeit P, Gorman DN, Gao P, Saleheen D, Rendon A, Nelson CP, Braund PS, Hall AS, Chasman DI, Tybjærg-Hansen A, Chambers JC, Benjamin EJ, Franks PW, Clarke R, Wilde AA, Trip MD, Steri M, Witteman JC, Qi L, van der Schoot CE, de Faire U, Erdmann J, Stringham HM, Koenig W, Rader DJ, Melzer D, Reich D, Psaty BM, Kleber ME, Panagiotakos DB, Willeit J, Wennberg P, Woodward M, Adamovic S, Rimm EB, Meade TW, Gillum RF, Shaffer JA, Hofman A, Onat A, Sundström J, Wassertheil-Smoller S, Mellström D, Gallacher J, Cushman M, Tracy RP, Kauhanen J, Karlsson M, Salonen JT, Wilhelmsen L, Amouyel P, Cantin B, Best LG, Ben-Shlomo Y, Manson JE, Davey-Smith G, de Bakker PI, O’Donnell CJ, Wilson JF, Wilson AG, Assimes TL, Jansson JO, Ohlsson C, Tivesten Å, Ljunggren Ö, Reilly MP, Hamsten A, Ingelsson E, Cambien F, Hung J, Thomas GN, Boehnke M, Schunkert H, Asselbergs FW, Kastelein JJ, Gudnason V, Salomaa V, Harris TB, Kooner JS, Allin KH, Nordestgaard BG, Hopewell JC, Goodall AH, Ridker PM, Hólm H, Watkins H, Ouwehand WH, Samani NJ, Kaptoge S, Di Angelantonio E, Harari O, Danesh J (2012) Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379(9822):1205–1213. https://doi.org/10.1016/S0140-6736(11)61931-4
Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Swerdlow DI, Holmes MV, Kuchenbaecker KB, Engmann JE, Shah T, Sofat R, Guo Y, Chung C, Peasey A, Pfister R, Mooijaart SP, Ireland HA, Leusink M, Langenberg C, Li KW, Palmen J, Howard P, Cooper JA, Drenos F, Hardy J, Nalls MA, Li YR, Lowe G, Stewart M, Bielinski SJ, Peto J, Timpson NJ, Gallacher J, Dunlop M, Houlston R, Tomlinson I, Tzoulaki I, Luan J, Boer JM, Forouhi NG, Onland-Moret NC, van der Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Baceviciene M, Tamosiunas A, Pajak A, Topor-Madry R, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, de Faire U, Ferrucci L, Bandenelli S, Tanaka T, Meschia JF, Singleton A, Navis G, Mateo Leach I, Bakker SJ, Gansevoort RT, Ford I, Epstein SE, Burnett MS, Devaney JM, Jukema JW, Westendorp RG, Jan de Borst G, van der Graaf Y, de Jong PA, Mailand-van der Zee AH, Klungel OH, de Boer A, Doevendans PA, Stephens JW, Eaton CB, Robinson JG, Manson JE, Fowkes FG, Frayling TM, Price JF, Whincup PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Redline S, Lange LA, Kumari M, Wareham NJ, Verschuren WM, Benjamin EJ, Whittaker JC, Hamsten A, Dudbridge F, Delaney JA, Wong A, Kuh D, Hardy R, Castillo BA, Connolly JJ, van der Harst P, Brunner EJ, Marmot MG, Wassel CL, Humphries SE, Talmud PJ, Kivimaki M, Asselbergs FW, Voevoda M, Bobak M, Pikhart H, Wilson JG, Hakonarson H, Reiner AP, Keating BJ, Sattar N, Hingorani AD, Casas JP (2012) The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379(9822):1214–1224. https://doi.org/10.1016/S0140-6736(12)60110-X
Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M, Zangeneh F, Bush MA. (2017) American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease–Executive Summary. Endocr Pract 23(4):479-497 https://doi.org/10.4158/ep171764.gl. Complete Appendix to Guidelines http://journals.aace.com
Jeong SJ, Kim S, Park JG, Jung IH, Lee MN, Jeon S, Kweon HY, Yu DY, Lee SH, Jang Y, Kang SW, Han KH, Miller YI, Park YM, Cheong C, Choi JH, Oh GT (2018) Prdx1 (peroxiredoxin 1) deficiency reduces cholesterol efflux via impaired macrophage lipophagic flux. Autophagy 14(1):120–133. https://doi.org/10.1080/15548627.2017.1327942
Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG (2009) Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301(22):2331–2339. https://doi.org/10.1001/jama.2009.801
Kastelein JJ, Sager PT, de Groot E, Veltri E (2005) Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J 149(2):234–239. https://doi.org/10.1016/j.ahj.2004.06.024
Kawashiri SY, Kawakami A, Yamasaki S, Imazato T, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Nakamura H, Ida H, Origuchi T, Ueki Y, Eguchi K (2011) Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int 31(4):451–456. https://doi.org/10.1007/s00296-009-1303-y
Kotwal S, Jun M, Sullivan D, Perkovic V, Neal B (2012) Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcome 5(6):808–818. https://doi.org/10.1161/CIRCOUTCOMES.112.966168
Kromhout D, Giltay EJ, Geleijnse JM, Alpha Omega Trial G (2010) n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 363(21):2015–2026. https://doi.org/10.1056/NEJMoa1003603
Kronenberg F, Utermann G (2013) Lipoprotein(a): resurrected by genetics. J Intern Med 273(1):6–30. https://doi.org/10.1111/j.1365-2796.2012.02592.x
Kwak SM, Myung SK, Lee YJ, Seo HG, Korean Meta-analysis Study G (2012) Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 172(9):686–694. https://doi.org/10.1001/archinternmed.2012.262
Kwon GP, Schroeder JL, Amar MJ, Remaley AT, Balaban RS (2008) Contribution of macromolecular structure to the retention of low-density lipoprotein at arterial branch points. Circulation 117(22):2919–2927. https://doi.org/10.1161/CIRCULATIONAHA.107.754614
Lee EC, Desai U, Gololobov G, Hong S, Feng X, Yu XC, Gay J, Wilganowski N, Gao C, Du LL, Chen J, Hu Y, Zhao S, Kirkpatrick L, Schneider M, Zambrowicz BP, Landes G, Powell DR, Sonnenburg WK (2009) Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL). J Biol Chem 284(20):13735–13745. https://doi.org/10.1074/jbc.M807899200
Lee MR, Lim CJ, Lee YH, Park JG, Sonn SK, Lee MN, Jung IH, Jeong SJ, Jeon S, Lee M, Oh KS, Yang Y, Kim JB, Choi HS, Jeong W, Jeong TS, Yoon WK, Kim HC, Choi JH, Oh GT (2014) The adipokine Retnla modulates cholesterol homeostasis in hyperlipidemic mice. Nat Commun 5:4410. https://doi.org/10.1038/ncomms5410
Libby P (2017) Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of CANTOS and beyond. J Am Coll Cardiol 70(18):2278–2289. https://doi.org/10.1016/j.jacc.2017.09.028
Libby P, Warner SJ, Friedman GB (1988) Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Investig 81(2):487–498. https://doi.org/10.1172/JCI113346
Libby P, Aikawa M, Schonbeck U (2000) Cholesterol and atherosclerosis. Biochem Biophys Acta 1529(1–3):299–309
Libby P, Ridker PM, Hansson GK (2011) Progress and challenges in translating the biology of atherosclerosis. Nature 473(7347):317–325. https://doi.org/10.1038/nature10146
Long-Term Intervention with Pravastatin in Ischaemic Disease Study G (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339(19):1349–1357. https://doi.org/10.1056/NEJM199811053391902
Lp-PLA(2) Studies Collaboration, Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J (2010) Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375(9725):1536–1544. https://doi.org/10.1016/S0140-6736(10)60319-4
Mariathasan S, Monack DM (2007) Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 7(1):31–40. https://doi.org/10.1038/nri1997
McGowan MP, Tardif JC, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, Wagener G, Chasan-Taber S (2012) Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS ONE 7(11):e49006. https://doi.org/10.1371/journal.pone.0049006
Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernán MA, Ridker PM, Mozaffarian D (2011) Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 108(9):1362–1370. https://doi.org/10.1016/j.amjcard.2011.06.054
Mills EJ, O’Regan C, Eyawo O, Wu P, Mills F, Berwanger O, Briel M (2011) Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of > 40 000 patients. Eur Heart J 32(11):1409–1415. https://doi.org/10.1093/eurheartj/ehr035
Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A, Investigators Darapladib (2008) The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 51(17):1632–1641. https://doi.org/10.1016/j.jacc.2007.11.079
Moore KJ, Tabas I (2011) Macrophages in the pathogenesis of atherosclerosis. Cell 145(3):341–355. https://doi.org/10.1016/j.cell.2011.04.005
Mozaffarian D, Wu JH (2012) (n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary? J Nutr 142(3):614S–625S. https://doi.org/10.3945/jn.111.149633
Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, Brockmeyer M, Kandzari DE, Kubica JM, D’Agostino RB Sr, Kubica J, Volpe M, Agewall S, Kereiakes DJ, Kelm M (2015) Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 163(1):40–51. https://doi.org/10.7326/M14-2957
Nelson RH (2013) Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care 40(1):195–211. https://doi.org/10.1016/j.pop.2012.11.003
Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE (2011) Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med 365(22):2078–2087. https://doi.org/10.1056/NEJMoa1110874
Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE (2016) Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 316(22):2373–2384. https://doi.org/10.1001/jama.2016.16951
Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Pedersen TR, Ridker PM, Ray K, Karlson BW, Lundström T, Wolski K, Nissen SE (2018) Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial. Clin Cardiol 41(10):1281–1288. https://doi.org/10.1002/clc.23055
Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T, Matsuzawa Y (2002) Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106(22):2767–2770
Okamoto Y, Folco EJ, Minami M, Wara AK, Feinberg MW, Sukhova GK, Colvin RA, Kihara S, Funahashi T, Luster AD, Libby P (2008) Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res 102(2):218–225. https://doi.org/10.1161/CIRCRESAHA.107.164988
Pandor A, Ara RM, Tumur I, Wilkinson AJ, Paisley S, Duenas A, Durrington PN, Chilcott J (2009) Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med 265(5):568–580. https://doi.org/10.1111/j.1365-2796.2008.02062.x
Park JG, Oh GT (2011) The role of peroxidases in the pathogenesis of atherosclerosis. BMB Rep 44(8):497–505
Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, Pyörälä K, Miettinen T, Wilhelmsen L, Olsson AG, Wedel H, Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344(8934):1383–1389
Petersen AM, Pedersen BK (2005) The anti-inflammatory effect of exercise. J Appl Physiol 98(4):1154–1162. https://doi.org/10.1152/japplphysiol.00164.2004
Phan BA, Dayspring TD, Toth PP (2012) Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manage 8:415–427. https://doi.org/10.2147/VHRM.S33664
Pinkosky SL, Filippov S, Srivastava RA, Hanselman JC, Bradshaw CD, Hurley TR, Cramer CT, Spahr MA, Brant AF, Houghton JL, Baker C, Naples M, Adeli K, Newton RS (2013) AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res 54(1):134–151. https://doi.org/10.1194/jlr.M030528
Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, Birch CM, Smith BK, Filippov S, Groot PH, Steinberg GR, Lalwani ND (2016) Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun 7:13457. https://doi.org/10.1038/ncomms13457
Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375(9719):998–1006. https://doi.org/10.1016/S0140-6736(10)60284-X
Rader DJ, Kastelein JJ (2014) Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 129(9):1022–1032. https://doi.org/10.1161/CIRCULATIONAHA.113.001292
Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, Hall T, Troquay RP, Turner T, Visseren FL, Wijngaard P, Wright RS, Kastelein JJ (2017) Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med 376(15):1430–1440. https://doi.org/10.1056/NEJMoa1615758
Rho YH, Oeser A, Chung CP, Milne GL, Stein CM (2009) Drugs used in the treatment of rheumatoid arthritis: relationship between current use and cardiovascular risk factors. Arch Drug Inf 2(2):34–40. https://doi.org/10.1111/j.1753-5174.2009.00019.x
Ridker PM (2016) From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res 118(1):145–156. https://doi.org/10.1161/CIRCRESAHA.115.306656
Ridker PM, Luscher TF (2014) Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 35(27):1782–1791. https://doi.org/10.1093/eurheartj/ehu203
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359(21):2195–2207. https://doi.org/10.1056/NEJMoa0807646
Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, Thuren T, CANTOS Pilot Investigative Group (2012) Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126(23):2739–2748. https://doi.org/10.1161/CIRCULATIONAHA.112.122556
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, CANTOS Trial Group (2017a) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377(12):1119–1131. https://doi.org/10.1056/NEJMoa1707914
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC, SPIRE Cardiovascular Outcome Investigators (2017b) Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med 376(16):1527–1539. https://doi.org/10.1056/NEJMoa1701488
Robciuc MR, Maranghi M, Lahikainen A, Rader D, Bensadoun A, Öörni K, Metso J, Minicocci I, Ciociola E, Ceci F, Montali A, Arca M, Ehnholm C, Jauhiainen M (2013) Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arterioscler Thromb Vasc Biol 33(7):1706–1713. https://doi.org/10.1161/ATVBAHA.113.301397
Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ, ODYSSEY LONG TERM Investigators (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1489–1499. https://doi.org/10.1056/NEJMoa1501031
Rosenson RS (2010) Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes. Curr Opin Lipidol 21(6):473–480. https://doi.org/10.1097/MOL.0b013e32833eb581
Rosenson RS, Hurt-Camejo E (2012) Phospholipase A2 enzymes and the risk of atherosclerosis. Eur Heart J 33(23):2899–2909. https://doi.org/10.1093/eurheartj/ehs148
Rosenson RS, Stafforini DM (2012) Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J Lipid Res 53(9):1767–1782. https://doi.org/10.1194/jlr.R024190
Rosenson RS, Hislop C, Elliott M, Stasiv Y, Goulder M, Waters D (2010) Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J Am Coll Cardiol 56(14):1079–1088. https://doi.org/10.1016/j.jacc.2010.06.015
Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R, SEAS Investigators (2008) Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 359(13):1343–1356. https://doi.org/10.1056/NEJMoa0804602
Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM (1991) Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353(6341):265–267. https://doi.org/10.1038/353265a0
Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O’Dell J, Turkiewicz AM, Furst DE, American College of Rheumatology (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthr Rheum 59(6):762–784. https://doi.org/10.1002/art.23721
Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1500–1509. https://doi.org/10.1056/NEJMoa1500858
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376(18):1713–1722. https://doi.org/10.1056/NEJMoa1615664
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335(14):1001–1009. https://doi.org/10.1056/NEJM199610033351401
Sakakura K, Nakano M, Otsuka F, Ladich E, Kolodgie FD, Virmani R (2013) Pathophysiology of atherosclerosis plaque progression. Heart Lung Circ 22(6):399–411. https://doi.org/10.1016/j.hlc.2013.03.001
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM, ODYSSEY OUTCOMES Committees and Investigators (2018) Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. https://doi.org/10.1056/NEJMoa1801174
Seidah NG, Awan Z, Chretien M, Mbikay M (2014) PCSK9: a key modulator of cardiovascular health. Circ Res 114(6):1022–1036. https://doi.org/10.1161/CIRCRESAHA.114.301621
Serruys PW, García-García HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Bøtker HE, von Birgelen C, D’Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A, Integrated Biomarker and Imaging Study-2 Investigators (2008) Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118(11):1172–1182. https://doi.org/10.1161/CIRCULATIONAHA.108.771899
Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J, ASCOT investigators (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361(9364):1149–1158. https://doi.org/10.1016/S0140-6736(03)12948-0
Shapiro MD, Fazio S (2016) From lipids to inflammation: new approaches to reducing atherosclerotic risk. Circ Res 118(4):732–749. https://doi.org/10.1161/CIRCRESAHA.115.306471
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333(20):1301–1307. https://doi.org/10.1056/NEJM199511163332001
Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, PROSPER study group, PROspective Study of Pravastatin in the Elderly at Risk (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360(9346):1623–1630
Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O’Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64(5):625–639. https://doi.org/10.1002/acr.21641
Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, Chin W, Tribble DL, McGowan M (2012) Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 126(19):2283–2292. https://doi.org/10.1161/CIRCULATIONAHA.112.104125
Strang AC, Bisoendial RJ, Kootte RS, Schulte DM, Dallinga-Thie GM, Levels JH, Kok M, Vos K, Tas SW, Tietge UJ, Müller N, Laudes M, Gerlag DM, Stroes ES, Tak PP (2013) Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis 229(1):174–181. https://doi.org/10.1016/j.atherosclerosis.2013.04.031
Tanaka T, Narazaki M, Kishimoto T (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6(10):a016295. https://doi.org/10.1101/cshperspect.a016295
Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G, Gissi-HF Investigators (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372(9645):1223–1230. https://doi.org/10.1016/S0140-6736(08)61239-8
Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M (2013) Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 62(23):2178–2184. https://doi.org/10.1016/j.jacc.2013.07.081
Thompson PD, MacDougall DE, Newton RS, Margulies JR, Hanselman JC, Orloff DG, McKenney JM, Ballantyne CM (2016) Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol 10(3):556–567. https://doi.org/10.1016/j.jacl.2015.12.025
Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB (2005) Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 353(1):46–57. https://doi.org/10.1056/NEJMoa043175
Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, Komura N, Sakamoto K, Oka H, Nakao K, Nakamura S, Ishihara M, Matsui K, Sakaino N, Nakamura N, Yamamoto N, Koide S, Matsumura T, Fujimoto K, Tsunoda R, Morikami Y, Matsuyama K, Oshima S, Kaikita K, Hokimoto S, Ogawa H, PRECISE–IVUS Investigators (2015) Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol 66(5):495–507. https://doi.org/10.1016/j.jacc.2015.05.065
Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S (2016) Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388(10057):2239–2253. https://doi.org/10.1016/S0140-6736(16)31009-1
Weber C, Noels H (2011) Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17(11):1410–1422. https://doi.org/10.1038/nm.2538
Ylä-Herttuala S, Bentzon JF, Daemen M, Falk E, Garcia-Garcia HM, Herrmann J, Hoefer I, Jukema JW, Krams R, Kwak BR, Marx N, Naruszewicz M, Newby A, Pasterkamp G, Serruys PW, Waltenberger J, Weber C, Tokgözoglu L (2011) Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology. Thromb Haemost 106(1):1–19. https://doi.org/10.1160/TH10-12-0784
Yokota S, Itoh Y, Morio T, Origasa H, Sumitomo N, Tomobe M, Tanaka K, Minota S (2016) Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis 75(9):1654–1660. https://doi.org/10.1136/annrheumdis-2015-207818
Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Japan EPA lipid intervention study (JELIS) Investigators (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369(9567):1090–1098. https://doi.org/10.1016/S0140-6736(07)60527-3
Acknowledgements
This study was supported by a National Research Foundation of Korea (NRF) Grant funded by the Korean government (Nos.2012R1A3A2026454, 2018R1C1B6005004) and by a Grant from the Korea Research Institute of Bioscience and Biotechnology.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no potential conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Park, JG., Oh, G.T. Current pharmacotherapies for atherosclerotic cardiovascular diseases. Arch. Pharm. Res. 42, 206–223 (2019). https://doi.org/10.1007/s12272-019-01116-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-019-01116-1